Exact Sciences Corp Stock Price, News & Analysis

Exact Sciences Corp. reported first-quarter 2021 revenue of $402.1 million, up 16% from $347.8 million in Q1 2020. Screening revenue grew by 10% to $240.3 million, while Precision Oncology revenue increased by 1% to $129.4 million. COVID-19 testing contributed $32.3 million. The gross margin was 68%, with a non-GAAP gross margin of 73%. The income tax benefit was $242.8 million, leading to a net loss of $31.2 million, improved from $134.6 million in the prior year. The company forecasts full-year revenue between $1,690 million and $1,735 million.

Exact Sciences Corp. (Nasdaq: EXAS) announced management will participate in two upcoming investor conferences in May 2021. The BofA Securities Virtual Healthcare Conference will feature a fireside chat on May 12 at 1:15 p.m. EDT, while the UBS Global Healthcare Virtual Conference will take place on May 25 at 4:00 p.m. EDT. Investors can access the webcasts through the investor relations section of the Exact Sciences website. Exact Sciences focuses on cancer screening and diagnostic tests, aiming to enhance patient care and combat deadly cancers.

Exact Sciences (NASDAQ: EXAS) announced that Cologuard is the most cost-effective colorectal cancer screening option for the Alaska Native population, according to a study published in Mayo Clinic Proceedings. The study demonstrates that Cologuard, a non-invasive stool DNA test, produces the highest number of quality-adjusted life years (QALYs) and significantly reduces colorectal cancer incidence compared to colonoscopy and fecal immunochemical test (FIT). With challenges in screening adherence, Cologuard’s home-use capability presents a promising solution for increasing screening rates.

Exact Sciences Corp. (NASDAQ: EXAS) announced the successful acquisition of Ashion Analytics, enhancing its capabilities in precision oncology. This acquisition includes a CLIA-certified lab and advanced genomic testing options, specifically the GEM ExTra® test. The collaboration with The Translational Genomics Research Institute (TGen) aims to improve advanced cancer diagnostics. This strategic move is projected to bolster patient care and extend Exact Sciences' market leadership in cancer treatment.

Exact Sciences Corp. (Nasdaq: EXAS) will release its first quarter 2021 financial results on May 4, 2021, after the U.S. markets close. Following this, a webcast and conference call will be held at 5 p.m. EDT to discuss the results and business developments. The company focuses on cancer screening and diagnostics, leveraging successful products like Cologuard and Oncotype DX. Exact Sciences aims to enhance patient care through innovative solutions and continued investment in its product pipeline.

Exact Sciences Corp. (Nasdaq: EXAS) announced its participation in two upcoming virtual investor conferences. The company will hold a fireside chat at the Cowen 41st Annual Health Care Conference on March 2, 2021, at 11:50 a.m. EST, and at the Barclays Global Healthcare Conference on March 9, 2021, at 9:10 a.m. EST.

Investors can access the webcasts via the investor relations section of Exact Sciences' website. The company continues to focus on cancer screening and diagnostic tests to improve patient care.

Exact Sciences Corp. (Nasdaq: EXAS) reported fourth-quarter 2020 revenue of $466.3 million, with full-year revenue reaching $1.49 billion. Q4 screening revenue grew by 9% to $249.7 million, while COVID-19 testing contributed $99.1 million. However, the company faced a net loss of $436.8 million, or $(2.79) per share, compared to a net income of $78.0 million last year. The acquisition of Base Genomics resulted in a $412.6 million research and development charge. Cash reserves stood at $1.84 billion.

Exact Sciences Corp. (Nasdaq: EXAS) announced its acquisition of Ashion Analytics from The Translational Genomics Research Institute (TGen). Ashion, a CLIA-certified sequencing lab, will enhance Exact's precision oncology portfolio, particularly in minimal residual disease (MRD) testing. The acquisition includes a 10-year research collaboration with TGen and City of Hope to develop advanced MRD testing. This partnership aims to expedite bringing innovative genomic solutions to cancer treatment, leveraging Ashion's expertise and TARDIS technology.

Exact Sciences Corp. (Nasdaq: EXAS) is set to release its fourth quarter 2020 financial results on February 16, 2021, after U.S. market close. Management will host a webcast and conference call at 5 p.m. EST to discuss the financial results and business progress. The company is a leading provider of cancer screening and diagnostic tests, with an emphasis on improving patient care through products like Cologuard and Oncotype DX. For further details, visit their official website.